BioNTech Stock Slips Despite Q4 Beats
Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...
8h
Fintel on MSNCitigroup Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Buy RecommendationFintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...
BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...
(RTTNews) - BioNTech SE (BNTX) announced a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. The company's earnings totaled $259.5 million ...
BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...
We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...
Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results